TrialHarm reduction journal2023

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.

Mark K Greenwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.